Accordingly, international guidelines recommend thyroid hormone replacement therapy to be considered in adults whose TSH levels are above 10 mIU/L, as well as when TSH levels are lower if the patient is young, symptomatic or has other indications for prescribing this therapy, such as cardiovascular disease or antibodies to thyroid peroxidase [45]. This evidence concerns the gene TPO and cardiovascular disorder.